Cronos Group Inc vs Lam Research Corporation — how do they compare? Cronos Group Inc trades at $2.78 (market cap $1.02B), while Lam Research Corporation trades at $330.47 (market cap $432.82B). The key difference: Lam Research Corporation is far larger — about 424.3× Cronos Group Inc's market cap, and Lam Research Corporation pays a 0.3% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals.
| CRON | LRCX | |
|---|---|---|
Market Cap | $1.02B | $432.82B |
Sector | Health | Technology |
52-Week High | $3.27 | $433.33 |
52-Week Low | $1.95 | $94.84 |
Enterprise Value | $203.29M | $431.81B |
Dividend Yield | — | 0.3% |
Signals from Pluang's Aura AI — not financial advice
CRON trades at $2.75, showing no change recently. The stock has a mixed technical outlook with a neutral overall signal but bullish moving averages. Fundamentally, revenue grew to $146.59M in 2025, but net income was negative at -$9.45M. Recent news highlights strong Q1 2026 revenue growth of 40% and expansion of its Spinach brand portfolio, though the company faces intense cannabis sector competition.
Outlook is cautious with growth potential from international expansion and market share gains, but profitability remains a challenge. Risks include regulatory uncertainty and competitive pressures. Analyst sentiment is mixed with 60% hold ratings. The stock presents a speculative opportunity for investors betting on continued top-line growth and eventual margin improvement.
Lam Research (LRCX) trades at $329.92, down 5.83% amid broader semiconductor sector volatility. The stock shows strong fundamentals with Q1 2026 EPS of $1.47 beating estimates by 8%, marking the third consecutive quarterly beat. Revenue grew 23.8% year-over-year to $18.44B in 2025, while net income margin expanded to 30.94%. Technical indicators show bearish momentum with the stock trading below key resistance at $332, though RSI at 22.63 suggests potential oversold conditions. Recent news highlights AI-driven demand for semiconductor equipment as a key growth catalyst.
LRCX presents a compelling long-term opportunity with 78% analyst buy ratings and $393 consensus price target (19% upside), though elevated P/E of 62.37 warrants caution. Strong cash flow generation ($6.17B operating cash flow) supports dividend payments and strategic investments. Risks include semiconductor cycle volatility and competitive pressures, but AI infrastructure spending provides durable tailwinds for the wafer fabrication equipment leader.
Trailing returns across standard periods
Latest headlines on both assets
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →Lam Research manufactures equipment used to fabricate semiconductors. The firm is focused on the etching, deposition, and clean markets, which are key steps in the semiconductor manufacturing process, especially for 3D NAND flash storage, advanced DRAM, and leading-edge logic/foundry chipmakers. Lam's flagship Kiyo, Vector, and Sabre products are sold in all major geographies to key customers such as Samsung Electronics, Micron, Intel, and Taiwan Semiconductor Manufacturing.
Read more on LRCX →